Gainesville, Ga. – January 26, 2026

Bend Bioscience, a U.S. based small molecule pharmaceutical CDMO, held a ceremonial groundbreaking late last week to mark the start of a 28,000 square foot expansion of its FDA & DEA approved facility that will enhance commercial spray drying capabilities and increase capacity for complex oral solid dose drug products.

The site’s expansion reinforces Bend Bioscience’s long-term investment in domestic pharmaceutical manufacturing and positions the company to better serve clients across the pharmaceutical development lifecycle, from early formulation through commercial launch.

“This expansion reflects our mission in action,” said Owen Murray, CEO of Bend Bioscience. “We’re scaling with purpose — not just adding square footage, but building smarter, technologically advanced responsive infrastructure to help our clients advance life-changing therapies with greater speed, reliability, and scientific rigor. We’re proud to continue growing here in Georgia, in partnership with the local community and for the patients we ultimately serve.”

This milestone also reflects Bend Bioscience’s broader commitment to workforce development in the region, including its apprenticeship partnership with Lanier Technical College and efforts to invest in local talent.

“This investment marks another milestone in Gainesville’s life sciences legacy,” said Mayor Zack Thompson. “The Bend Bioscience expansion brings high-quality jobs, strengthens our economy, and underscores why innovative companies continue to choose Gainesville. Bend’s Gainesville facility has offered generational opportunities in pharmaceutical manufacturing for 45 years, and this investment reconfirms their commitment to our community and their Gainesville team.”

The new facility will include a state-of-the-art spray dryer system, purpose-built for scaling bioavailability-enhanced formulations such as amorphous solid dispersions. It will also support expanded capacity for potent compound handling and integrated manufacturing flows that streamline tech transfer and scale-up. This site expansion complements Bend Bioscience’s national footprint, integrating seamlessly with our other facilities to offer end-to-end development and manufacturing solutions — from early formulation through commercial supply, all from one collaborative CDMO partner.

The Gainesville site will continue to operate under Bend Bioscience’s hallmark promise: High Science + High Service — combining bold science with operational excellence to accelerate drug development and manufacturing for small-molecule innovators.

About Bend Bioscience

Formed from three specialist CDMOs, the new Bend Bioscience offers bigger solutions and bolder science across small molecule capabilities and enabling technologies. From pre-clinical to commercial scale, Bend provides its clients with the highest levels of service and science, combining the broad capabilities of a large CDMO with the flexibility and speed of an expert partner. We employ our scientific expertise to optimize your formulation designs with a focus on enhanced pharmacokinetics, and deploying enabling technologies such as spray dried dispersions, particle engineering, multi-particulate dosage forms and modified release technologies to affect desired release profiles and in vivo bioavailability. Our partnering approach brings molecules through the clinic, to scaled manufacturing and launch through our network of three specialized, newly expanded facilities in the U.S., from where we offer accelerated solutions for orphan, breakthrough and specialty programs, as well as tech transfer expertise to ease transition from early development to commercial production.

Media Contacts:
Chris Halling
Orientation Marketing Ltd.
t: +44 (0)7580 041073
e: chris.halling@orientation.agency